Idera Pharmaceuticals, Inc.
167 Sidney Street
About Idera Pharmaceuticals, Inc.Idera Pharma develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.
For more information, visit www.iderapharma.com.
366 articles with Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. Secures $19.5 Million In Funding; Proceeds To Fund Clinical Programs Targeting Toll-Like Receptors
Idera Pharmaceuticals, Inc. to Present At Rodman And Renshaw Techvest 7th Annual Healthcare Conference
Idera Pharmaceuticals, Inc. Initiates Phase 1/2 Oncology Trial Of HYB2055 In Combination With Chemotherapy Agents Gemcitabine And Carboplatin